Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III safety and immunogenicity of unadjuvanted RSV maternal vaccine in high-risk pregnant women
2021-000994-96Phase 3Completed
- Sponsor
- GSK
- Start
- May 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing RSV MAT maternal vaccine with Placebo (2 arms). Primary endpoint: Solicited administration site events in maternal participants. Started May 2021; status: completed.
02
Drugs
RSVPreF3
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2021-000994-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000994-96.